BofA Securities analyst Jason Zemansky raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $9.00 (from $8.00) while maintaining a Buy rating.

The analyst commented, "In our view, Rocket's call this morning to discuss Kresladi's approval didn't provide many new updates, making the stock’s reaction (-20% vs. NBI -2%) surprising to us. The team largely reiterated prior messaging, notably guiding to a single‑digit annual treatment population—a function of both the ultra‑rare nature of LAD‑I and the complexity administering of an ex‑vivo gene therapy. We acknowledge details around timelines (commercial availability is not expected until 4Q, with revenues unlikely before 2027) and the lack of pricing commentary may have disappointed. That said, with Kresladi never expected to be a meaningful P&L driver to begin with, we had framed the approval’s key benefits as 1) validation of management’s ability to execute and 2) the generation of a PRV—both of which were successfully achieved."